Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases.

Dengue virus (DENV) is the leading cause of arboviral diseases in humans worldwide. The envelope (E) protein of DENV is the major target of neutralizing antibodies (Abs). Previous studies have shown that a significant proportion of anti-E Abs in human serum after DENV infection recognize the highly...

Full description

Bibliographic Details
Main Authors: Chih-Yun Lai, Katherine L Williams, Yi-Chieh Wu, Sarah Knight, Angel Balmaseda, Eva Harris, Wei-Kung Wang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS Neglected Tropical Diseases
Online Access:http://europepmc.org/articles/PMC3777924?pdf=render
id doaj-ae6758c3cfa54247a2615c5ff0513a27
record_format Article
spelling doaj-ae6758c3cfa54247a2615c5ff0513a272020-11-24T21:41:28ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352013-01-0179e245110.1371/journal.pntd.0002451Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases.Chih-Yun LaiKatherine L WilliamsYi-Chieh WuSarah KnightAngel BalmasedaEva HarrisWei-Kung WangDengue virus (DENV) is the leading cause of arboviral diseases in humans worldwide. The envelope (E) protein of DENV is the major target of neutralizing antibodies (Abs). Previous studies have shown that a significant proportion of anti-E Abs in human serum after DENV infection recognize the highly conserved fusion loop (FL) of E protein. The role of anti-FL Abs in protection against subsequent DENV infection versus pathogenesis remains unclear. A human anti-E monoclonal Ab was used as a standard in a virion-capture ELISA to measure the concentration of anti-E Abs, [anti-E Abs], in dengue-immune sera from Nicaraguan patients collected 3, 6, 12 and 18 months post-infection. The proportion of anti-FL Abs was determined by capture ELISA using virus-like particles containing mutations in FL, and the concentration of anti-FL Abs, [anti-FL Abs], was calculated. Neutralization titers (NT50) were determined using a previously described flow cytometry-based assay. Analysis of sequential samples from 10 dengue patients revealed [anti-E Abs] and [anti-FL Abs] were higher in secondary than in primary DENV infections. While [anti-FL Abs] did not correlate with NT50 against the current infecting serotype, it correlated with NT50 against the serotypes to which patients had likely not yet been exposed ("non-exposed" serotypes) in 14 secondary DENV3 and 15 secondary DENV2 cases. These findings demonstrate the kinetics of anti-FL Abs and provide evidence that anti-FL Abs play a protective role against "non-exposed" serotypes after secondary DENV infection.http://europepmc.org/articles/PMC3777924?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Chih-Yun Lai
Katherine L Williams
Yi-Chieh Wu
Sarah Knight
Angel Balmaseda
Eva Harris
Wei-Kung Wang
spellingShingle Chih-Yun Lai
Katherine L Williams
Yi-Chieh Wu
Sarah Knight
Angel Balmaseda
Eva Harris
Wei-Kung Wang
Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases.
PLoS Neglected Tropical Diseases
author_facet Chih-Yun Lai
Katherine L Williams
Yi-Chieh Wu
Sarah Knight
Angel Balmaseda
Eva Harris
Wei-Kung Wang
author_sort Chih-Yun Lai
title Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases.
title_short Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases.
title_full Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases.
title_fullStr Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases.
title_full_unstemmed Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases.
title_sort analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in nicaraguan dengue cases.
publisher Public Library of Science (PLoS)
series PLoS Neglected Tropical Diseases
issn 1935-2727
1935-2735
publishDate 2013-01-01
description Dengue virus (DENV) is the leading cause of arboviral diseases in humans worldwide. The envelope (E) protein of DENV is the major target of neutralizing antibodies (Abs). Previous studies have shown that a significant proportion of anti-E Abs in human serum after DENV infection recognize the highly conserved fusion loop (FL) of E protein. The role of anti-FL Abs in protection against subsequent DENV infection versus pathogenesis remains unclear. A human anti-E monoclonal Ab was used as a standard in a virion-capture ELISA to measure the concentration of anti-E Abs, [anti-E Abs], in dengue-immune sera from Nicaraguan patients collected 3, 6, 12 and 18 months post-infection. The proportion of anti-FL Abs was determined by capture ELISA using virus-like particles containing mutations in FL, and the concentration of anti-FL Abs, [anti-FL Abs], was calculated. Neutralization titers (NT50) were determined using a previously described flow cytometry-based assay. Analysis of sequential samples from 10 dengue patients revealed [anti-E Abs] and [anti-FL Abs] were higher in secondary than in primary DENV infections. While [anti-FL Abs] did not correlate with NT50 against the current infecting serotype, it correlated with NT50 against the serotypes to which patients had likely not yet been exposed ("non-exposed" serotypes) in 14 secondary DENV3 and 15 secondary DENV2 cases. These findings demonstrate the kinetics of anti-FL Abs and provide evidence that anti-FL Abs play a protective role against "non-exposed" serotypes after secondary DENV infection.
url http://europepmc.org/articles/PMC3777924?pdf=render
work_keys_str_mv AT chihyunlai analysisofcrossreactiveantibodiesrecognizingthefusionloopofenvelopeproteinandcorrelationwithneutralizingantibodytitersinnicaraguandenguecases
AT katherinelwilliams analysisofcrossreactiveantibodiesrecognizingthefusionloopofenvelopeproteinandcorrelationwithneutralizingantibodytitersinnicaraguandenguecases
AT yichiehwu analysisofcrossreactiveantibodiesrecognizingthefusionloopofenvelopeproteinandcorrelationwithneutralizingantibodytitersinnicaraguandenguecases
AT sarahknight analysisofcrossreactiveantibodiesrecognizingthefusionloopofenvelopeproteinandcorrelationwithneutralizingantibodytitersinnicaraguandenguecases
AT angelbalmaseda analysisofcrossreactiveantibodiesrecognizingthefusionloopofenvelopeproteinandcorrelationwithneutralizingantibodytitersinnicaraguandenguecases
AT evaharris analysisofcrossreactiveantibodiesrecognizingthefusionloopofenvelopeproteinandcorrelationwithneutralizingantibodytitersinnicaraguandenguecases
AT weikungwang analysisofcrossreactiveantibodiesrecognizingthefusionloopofenvelopeproteinandcorrelationwithneutralizingantibodytitersinnicaraguandenguecases
_version_ 1725921908175667200